Skip to main content
Journal cover image

Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials.

Publication ,  Journal Article
Smith, SA; Mentz, RJ; Roessig, L; Mebazza, A; Longrois, D; Gheorghiade, M; Pitt, B; Zannad, F; Butler, J; Abraham, WT
Published in: Am J Cardiol
October 15, 2015

Acute heart failure (AHF) is a complex syndrome with presentations ranging from hypotensive cardiogenic shock to hypertensive emergency with pulmonary edema. Most patients with AHF present with worsening of chronic HF signs and symptoms over days to weeks, and significant heterogeneity exists. It can, therefore, be challenging to characterize the overall population. The complexity of defining the AHF phenotype has been cited as a contributing cause for neutral results in most pharmacologic trials in patients with AHF. Dyspnea has been a routine inclusion criterion for AHF for over a decade, but the utility of current instruments for dyspnea assessment has been called into question. Furthermore, the threshold of clinical severity that prompts patient admission of an HF clinic visit may vary substantially across regions in global trials. Therefore, the inclusion of cardiac-specific biomarkers has been incorporated into AHF trials as 1 strategy to support inclusion of the target patient population and potentially enrich the population with patients at risk for clinical outcomes. In conclusion, we discuss strategies to support appropriate patient selection in AHF trials with an emphasis on using biomarker criteria that may improve the likelihood of success with future AHF clinical trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

October 15, 2015

Volume

116

Issue

8

Start / End Page

1304 / 1310

Location

United States

Related Subject Headings

  • Patient Selection
  • Natriuretic Peptides
  • Humans
  • Heart Failure
  • Clinical Trials as Topic
  • Cardiovascular System & Hematology
  • Acute Disease
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Smith, S. A., Mentz, R. J., Roessig, L., Mebazza, A., Longrois, D., Gheorghiade, M., … Abraham, W. T. (2015). Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. Am J Cardiol, 116(8), 1304–1310. https://doi.org/10.1016/j.amjcard.2015.07.049
Smith, Sakima A., Robert J. Mentz, Lothar Roessig, Alexandre Mebazza, Dan Longrois, Mihai Gheorghiade, Bertram Pitt, Faiez Zannad, Javed Butler, and William T. Abraham. “Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials.Am J Cardiol 116, no. 8 (October 15, 2015): 1304–10. https://doi.org/10.1016/j.amjcard.2015.07.049.
Smith SA, Mentz RJ, Roessig L, Mebazza A, Longrois D, Gheorghiade M, et al. Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. Am J Cardiol. 2015 Oct 15;116(8):1304–10.
Smith, Sakima A., et al. “Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials.Am J Cardiol, vol. 116, no. 8, Oct. 2015, pp. 1304–10. Pubmed, doi:10.1016/j.amjcard.2015.07.049.
Smith SA, Mentz RJ, Roessig L, Mebazza A, Longrois D, Gheorghiade M, Pitt B, Zannad F, Butler J, Abraham WT. Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. Am J Cardiol. 2015 Oct 15;116(8):1304–1310.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

October 15, 2015

Volume

116

Issue

8

Start / End Page

1304 / 1310

Location

United States

Related Subject Headings

  • Patient Selection
  • Natriuretic Peptides
  • Humans
  • Heart Failure
  • Clinical Trials as Topic
  • Cardiovascular System & Hematology
  • Acute Disease
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology